Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...